Extrait

This trial will aim to answer the following questions: 1)Does a fractionated schedule of two doses of Mylotarg improve upon the current standard of 3mg/m2 on day 1 of course 1? 2)Does the addition of Ganetespib starting at course 2 improve outcomes? 3)Does the addition of either a short or long (maintenance) course of AC220 starting at course 2 improve outcomes? 4)Is MRD status following course 1 of clinical value? In particular, can outcomes be improved by intensifying treatment in patients who show evidence of residual disease following course 1 of treatment? 5)To compare a total of two versus three courses of treatment in patients who are in CR or CRi and MRD -ve after induction course 1 6)To assess the value of Reduced Intensity Allogenic Stem Cell Transplantation as consolidation for patients with a matched sibiling or 8/8 matched unrelated donor.

Critère d'inclusion

• Acute Myeloid Leukaemia High Risk Myelodysplastic Syndrome

Liens

• euctr
• isrctn
• ictrp
• euctr